Terms: = Pancreatic cancer AND GATA1, ERYF1, P15976, 2623, ENSG00000102145, NFE1, GF1
11 results:
1. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract] [Full Text] [Related]
2. HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in pancreatic cancer.
Pan P; Qin G; Wang B; Yu H; Chen J; Liu J; Bing K; Shen J; Ren D; Zhao Y; Xia W; Li H; Wu H; Zhou Y
Cancer Res; 2022 Dec; 82(24):4542-4554. PubMed ID: 36102738
[TBL] [Abstract] [Full Text] [Related]
3. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment.
Serda M; Malarz K; Mrozek-Wilczkiewicz A; Wojtyniak M; Musioł R; Curley SA
Sci Rep; 2020 Jan; 10(1):260. PubMed ID: 31937861
[TBL] [Abstract] [Full Text] [Related]
4. Population-based study of the prevalence and management of self-reported high pain scores in patients with non-resected pancreatic adenocarcinoma.
Tung S; Coburn NG; Davis LE; Mahar AL; Myrehaug S; Zhao H; Earle CC; Nathens A; Hallet J
Br J Surg; 2019 Nov; 106(12):1666-1675. PubMed ID: 31639208
[TBL] [Abstract] [Full Text] [Related]
5. Ribonuclease inhibitor 1 regulates erythropoiesis by controlling gata1 translation.
Chennupati V; Veiga DF; Maslowski KM; Andina N; Tardivel A; Yu EC; Stilinovic M; Simillion C; Duchosal MA; Quadroni M; Roberts I; Sankaran VG; MacDonald HR; Fasel N; Angelillo-Scherrer A; Schneider P; Hoang T; Allam R
J Clin Invest; 2018 Apr; 128(4):1597-1614. PubMed ID: 29408805
[TBL] [Abstract] [Full Text] [Related]
6. RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73.
Papaspyropoulos A; Bradley L; Thapa A; Leung CY; Toskas K; Koennig D; Pefani DE; Raso C; Grou C; Hamilton G; Vlahov N; Grawenda A; Haider S; Chauhan J; Buti L; Kanapin A; Lu X; Buffa F; Dianov G; von Kriegsheim A; Matallanas D; Samsonova A; Zernicka-Goetz M; O'Neill E
Nat Commun; 2018 Jan; 9(1):424. PubMed ID: 29382819
[TBL] [Abstract] [Full Text] [Related]
7. Protein-protein interaction and SNP analysis in intraductal papillary mucinous neoplasm.
Jiang P; Zang W; Wang L; Xu Y; Liu Y; Deng SX
Gene; 2013 Jan; 513(1):219-24. PubMed ID: 23107772
[TBL] [Abstract] [Full Text] [Related]
8. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.
Oliveira-Cunha M; Hadfield KD; Siriwardena AK; Newman W
Pancreas; 2012 Apr; 41(3):428-34. PubMed ID: 22422135
[TBL] [Abstract] [Full Text] [Related]
9. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells.
Kisfalvi K; Guha S; Rozengurt E
J Cell Physiol; 2005 Mar; 202(3):880-90. PubMed ID: 15389644
[TBL] [Abstract] [Full Text] [Related]
10. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
Guha S; Lunn JA; Santiskulvong C; Rozengurt E
Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
[TBL] [Abstract] [Full Text] [Related]
11. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1.
Guha S; Rey O; Rozengurt E
Cancer Res; 2002 Mar; 62(6):1632-40. PubMed ID: 11912133
[TBL] [Abstract] [Full Text] [Related]
